Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

74.57EUR
19 Jul 2019
Change (% chg)

€0.57 (+0.77%)
Prev Close
€74.00
Open
€74.20
Day's High
€74.57
Day's Low
€73.62
Volume
2,253,113
Avg. Vol
2,388,566
52-wk High
€80.44
52-wk Low
€71.32

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality... (more)

Overall

Beta: 0.93
Market Cap(Mil.): €108,903.00
Shares Outstanding(Mil.): 1,262.50
Dividend: 2.96
Yield (%): 3.43

Financials

  SASY.PA Industry Sector
P/E (TTM): 23.32 29.88 32.67
EPS (TTM): 3.70 -- --
ROI: 5.69 14.90 14.49
ROE: 8.50 16.02 15.79

Exclusive: Germany's Bayer seeks animal health merger with Elanco - sources

FRANKFURT/LONDON Bayer has approached U.S. drug firm Elanco Animal Health to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters.

09 Jul 2019

Exclusive: Germany's Bayer seeks animal health merger with Elanco - sources

FRANKFURT/LONDON Bayer has approached U.S. drug firm Elanco Animal Health to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters.

09 Jul 2019

EXCLUSIVE-Germany's Bayer seeks animal health merger with Elanco - sources

* Bayer likely to retain stake in merged entity - sources (Updates with share price reaction)

09 Jul 2019

EXCLUSIVE-Germany's Bayer seeks animal health merger with Elanco - sources

FRANKFURT/LONDON, July 9 Bayer has approached U.S. drug firm Elanco Animal Health to discuss a possible combination of their pet-health businesses to create an industry giant, three sources familiar with the matter told Reuters.

09 Jul 2019

Pfizer, Sanofi, to boost South African Biovac's vaccine output

CAPE TOWN South Africa's Biovac Institute will start local production of Sanofi's Hexaxim vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.

02 Jul 2019

CORRECTED-Pfizer, Sanofi, to boost South African Biovac's vaccine output

CAPE TOWN, July 2 South Africa's Biovac Institute will start local production of Sanofi's Hexaxim vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.

02 Jul 2019

Pfizer, Sanofi, to boost South African Biovac's vaccine output

CAPE TOWN, July 2 South Africa's Biovac Institute will start local production of Sanofi's Hexavalent vaccine next year and Pfizer's anti-pneumonia Prevnar 13 vaccine in 2021, boosting supply of life-saving drugs in its main market, its CEO said.

02 Jul 2019

FDA approves expanded label for Regeneron/Sanofi's Dupixent

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.

26 Jun 2019

UPDATE 2-FDA approves expanded label for Regeneron/Sanofi's Dupixent

June 26 The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.

26 Jun 2019

REFILE-FDA approves expanded label for Regeneron/Sanofi's Dupixent

June 26 The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, the companies said on Wednesday.

26 Jun 2019

Earnings vs. Estimates